This document is a publication of a European patent application (EP4504780A1) by Genentech, Inc., detailing "Dosing for treatment with anti-FCRH5/anti-CD3 bispecific antibodies." The publication date is March 11, 2026. The patent covers specific dosing methodologies for these types of therapeutic antibodies.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in the development and commercialization of bispecific antibodies, particularly those targeting FCRH5 and CD3. Companies should monitor patent filings in their therapeutic areas of interest for potential intellectual property considerations.